Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyEpithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinomaThe role of immune checkpoint inhibition in the treatment of ovarian cancerAdvances in Cancer Immunotherapy in Solid TumorsCurrent and potential imaging applications of ferumoxytol for magnetic resonance imaging.The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP studyImmunotherapy in head and neck cancer: aiming at EXTREME precision.A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanomaNuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Advances in neuro-oncology imaging.Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.Future perspectives in cancer immunotherapyImmune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.Advancing Cancer Therapy with Present and Emerging Immuno-Oncology ApproachesA phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsSystemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).Intralesional and systemic immunotherapy for metastatic melanoma.Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockadePeptide vaccines in cancer-old concept revisited.Responses to immune checkpoint inhibitors in nonagenarians.Pembrolizumab use for the treatment of advanced melanoma.The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.Resistance to immunotherapy: clouds in a bright sky.A review of the importance of immune responses in luminal B breast cancer.IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.Pembrolizumab (Keytruda)Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
P2860
Q26740567-A639C4FF-533D-4091-943B-CEA64F7436C4Q26745516-BF60F5F7-ABCB-48BF-AF8C-CB2A029DCF9BQ26849546-149D1052-DB43-4E9E-8C8F-46687B42EFFDQ28077924-3EC32EE7-4355-4F18-85D1-476993C0040AQ28080113-93D9E29C-FACA-4FD5-918A-5F7E338933DCQ30234702-53CF027E-FD06-4F5F-8055-A7CC8B2CBCBFQ31156299-18B45567-43AB-4728-AE47-0AB59D78CD17Q31158877-7613B0C7-167D-4CF6-BD31-E02E00F6531EQ33755947-9097F34E-49E5-4004-9138-A89BAD72885AQ33756244-E958B0E5-4570-4F36-B797-B640816C7FABQ33775322-E6D67308-82CD-4266-8DA2-BAB717FD4159Q33850467-2FFE1915-D0ED-41FE-8A12-45D50E784A44Q36339461-8EFEA386-1821-4A0B-B662-1354B979784AQ36413957-1534FA99-FB18-4A7B-A00E-8BD96C1B67D4Q37024590-5E754252-A750-49AA-A8B0-E65F8DB5828DQ37147632-6DED2418-BAE4-484A-BB84-76027D1E1059Q37589557-C266EC64-ADFB-413A-9BF4-CC2539D8C7DBQ37642460-12635F9F-FEB8-4936-A35A-270DA6C4F2F0Q37729968-479CBCFA-56E7-4292-9EDD-76F7362FC4D0Q38374778-4761A907-280D-47A1-87E0-9919A4FD85FDQ38666241-D6CDC6B3-1CBF-40E8-B97C-74F8F933544AQ38670719-F5A29189-E3FD-450A-838E-D2D4A761B133Q38689153-6865E801-0337-473B-94E5-A63056AEF3E0Q38726713-35EE8F95-AA8B-41CA-8F41-868496A833C2Q38733611-E429FE0D-9AA2-4DF1-B6C8-C43167062E1DQ38748974-85E4BA50-CD0E-489C-AE2D-FB7B005648D1Q38824017-F9C63731-EB28-4E8F-802F-D9141652EEB7Q38895586-3774AC59-355E-43A8-934E-891417F2ED63Q38931269-5D5C92EC-2466-403F-8F39-A8BCA2D55B67Q38948218-C5B0004F-34DD-403F-B3EB-32BB03396F32Q38962421-9C0581F9-8FA6-4038-93F7-442ED5B51EE9Q39035351-BEF04ACC-EC6D-432D-8A7C-371C49B49AB4Q39079683-BE3A3590-85AC-4972-994B-565325DFA9F8Q39190201-EFDE4D24-6CB7-4309-91A5-4A25DD825702Q39227781-54EC2894-487E-48DA-8313-28C82A7D0329Q39236810-7E4FD51E-EC22-48C3-A2E2-7587C76F4440Q39239484-1BE0701B-61F2-43E0-BC2E-FB3072771BD1Q39294822-51C6FF03-B1D5-4534-B1A4-9B234FCFCB5DQ39615516-E5D98C94-68D5-4BA9-B17E-7DCA0049DD43Q40060071-98D08077-CD18-4BD5-BB66-130C1E133356
P2860
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@en
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@nl
type
label
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@en
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@nl
prefLabel
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@en
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@nl
P2093
P2860
P50
P356
P1476
Evaluation of Immune-Related R ...... ma Treated With Pembrolizumab.
@en
P2093
Amita Patnaik
Andrea Perrone
Antoni Ribas
Darcy Hille
F Stephen Hodi
Jedd D Wolchok
Jeffrey S Weber
Omid Hamid
Peter Hersey
P2860
P304
P356
10.1200/JCO.2015.64.0391
P407
P577
2016-03-07T00:00:00Z